General Information
Jazz MDD
A 12-Week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Efficacy and Safety of Solriamfetol [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] to Improve Wakefulness in Adult Patients with Excessive Daytime Sleepiness Associated with Major Depressive Disorder with a 40-Week Open-label Safety Extension and Randomized Withdrawal Period”
| Protocol | JZP188-301 |
|---|---|
| Identifier | |
| UID | 78c9372d-bdd5-4dd4-9502-7ca3dbcfca2a |
| Status | Cancelled |
| Phase | |
| Category | Major Depressive Disorder / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2019-12-18 15:27 |
| Last Updated | 2019-12-18 15:27 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | No | |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Volk, Stephen | SVolk | No |
| Recruiter | - | No | |
| Coordinator | Lara, Edward | ELara | No |
| Regulatory | - | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Jazz Pharmaceuticals |
|---|---|
| Division | Jazz Pharmaceuticals |
| Team | Jazz Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Yellow |
| Currency | - |
